ARQTArcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) develops treatments for immuno-dermatology, focusing on conditions like atopic dermatitis. The company’s next major catalyst is the Q3 2026 Earnings Release, scheduled for November 3, 2026. This event will provide critical insight into the company’s financial performance and the progress of its key product, ZORYVE. The FDA’s acceptance of a supplemental application for ZORYVE’s expanded use in infants aged 3 to 24 months was recently announced, and the outcome of this regulatory milestone could influence investor sentiment.
- A public fact about that setup: Arcutis has a history of strong year-over-year revenue growth, but its stock has often reacted negatively to earnings reports that miss profit expectations or show sequential revenue declines.
- Scouter has modeled bull and bear paths into the next catalyst: The company’s stock is expected to trade between $23.62 and $26.10, with a 50% chance of the bull path materializing.
- Past catalysts on this name are scored in The Read: Arcutis’ stock has historically declined 8%–14% after earnings reports showed strong year-over-year ZORYVE sales growth but missed elevated profit expectations or revealed sequential revenue drops and wider losses, while regulatory updates without new data failed to move the stock.
The Read
Arcutis Biotherapeutics' stock has historically declined 8%–14% after earnings reports showed strong year-over-year ZORYVE sales growth but missed elevated profit expectations or revealed sequential revenue drops and wider losses, while regulatory updates without new data failed to move the stock.
The schedule
- Tue27Oct
- Thu3Dec
- Thu3Dec
- Tue9Feb
- Wed5May
- Wed4Aug
Past
- Sat10Oct
Actual outcome: Bull · $32.19 at outcome
ARQT experienced a significant short-term move likely driven by positive clinical trial results, which signaled strong efficacy or progress in its therapeutic development. The move suggests the data exceeded expectations, improving investor sentiment and positioning the stock for further gains in the near term. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-22: +31.4% from 2026-10-08 (~3.1σ). Target date 2026-10-19 reached; move through 2026-10-22 observed.
ARQT experienced a significant short-term move likely driven by positive clinical trial results, which signaled strong efficacy or progress in its therapeutic development. The move suggests the data exceeded expectations, improving investor sentiment and positioning the stock for further gains in the near term. [Market retrospective · Short-Term (6–10 days)] Updated observation 2026-10-22: +31.4% from 2026-10-08 (~3.1σ). Target date 2026-10-19 reached; move through 2026-10-22 observed.
- Wed5Aug
Actual outcome: Mixed · $26.46 at outcome
Arcutis Biotherapeutics reported Q2 2026 earnings of $0.11 per share, matching the estimate, with net product revenue of $129.9 million, up 59% year-over-year and 23% sequentially. The company raised its 2026 full-year net product sales guidance to $525 million–$540 million and received approval to expand ZORYVE's indication. However, the stock fell 2.4% from the event date to the outcome date, likely due to short-term profit-taking following the positive results and mixed market sentiment on the lack of significant surprises.
Q2 2026 Earnings Release focusing on ZORYVE sequential growth and whether Q1's seasonality weakness reverses.
- Wed6May
Actual outcome: Bear · $21.69 at outcome
Arcutis reported a Q1 2026 loss of $0.09 per share, missing consensus estimates of a $0.02 loss. Additionally, while ZORYVE net product revenue grew 65% year-over-year to $105.4 million, it declined 17% sequentially from Q4 2025 due to seasonality, which weighed on investor sentiment and drove a 10.3% decline in the stock.
- Wed6May
Actual outcome: Bear · $21.69 at outcome
Arcutis reported Q1 ZORYVE net product revenue of $105.4 million, representing a 65% year-over-year increase but a 17% sequential decline from Q4 2025. Additionally, the company reported a wider-than-expected quarterly loss of $0.09 per share versus consensus estimates of a $0.02 loss. The sequential revenue drop and failure to sustain recent profitability undermined the bull case, driving the stock below the $21.50 bear floor as investors questioned the company's growth momentum and margin trajectory.
- Wed15Apr
Actual outcome: Bear · $22.86 at outcome
The anticipated regulatory timeline update for roflumilast cream in atopic dermatitis did not materialize, as the company only announced its Q1 earnings call scheduled for May 6. In the absence of the expected fundamental catalyst or new clinical details, the stock remained flat and traded sideways between the bull and bear targets.
- Wed25Feb
Actual outcome: Bear · $24.76 at outcome
Arcutis reported Q4 2025 EPS of $0.14, matching consensus estimates, alongside strong ZORYVE net product revenues of $127.5 million (an 84% year-over-year increase). Despite the robust sales growth and transition to profitability, the stock fell 8.3% following the release. Given the company's premium valuation heading into the print, the in-line earnings result failed to meet elevated market expectations, leading to a sell-off.
